Abstract:The growing use of molecular imaging helps to control and monitor dosage for increased safety and effectiveness. Molecular imaging agents become the scientific tools for moving a concept from bench work to clinic product development. This special issue provides original research and review of new trends in molecular imaging agent development. Among clinic molecular imaging modalities, radionuclide imaging technique is the most sensitive and could provide target-specific information. The radiotracer could non-invasively assess disease treatment endpoints which used to rely almost exclusively on biopsies and histopathological assays. L.-H. Shen et al. (Taiwan) reviewed molecular imaging in the diagnosis and management of CNS disorders. F.-L. Kong et al. (USA), N. Tsao et al. (USA), and C.-L. Ho et al. (Taiwan) report pharmacokinetics and dosimetry of molecular imaging compounds in oncology. M.-H. Liao et al. (Taiwan), X. Wang et al. (China), C. Wu et al. (China) and M. Tian et al. (USA) reported that molecular imaging techniques play a major role in the development of novel therapies since they measure target expressions (apoptosis, glycolysis) as well as function, pathway activities, and cell migration in the intact organism. Y.-F. Wang et al. and M.-Y. Chao et al. (Taiwan) described the kit probe for 99mTc-labeling which is crucial for centralized drug process. The kit probe may allow theranostic concept. A theranostic agent would be more accurate in the evaluation of patient response to treatment. The radiotracer could also be used for radionuclide therapy as reported by C. Wang et al. (China). Hybrid molecular imaging modalities (PET/CT, SPECT/CT) provide high-sensitivity functional and high-resolution anatomical imaging which are important in design-personalized treatment. M.-C. Chen et al. (Taiwan) reported the value of using I-131 NP-59 SPECT/CT to diagnose patients with subclinical or atypical features of primary aldosteronism. To proof of concept for molecular biology findings using different imaging modalities (optical, sonography) were described by Z. Pu et al. (China). In summary, molecular imaging enables the comprehensive characterization of therapeutic intervention and can be used in preclinical studies, pharmacokinetic studies, dose-finding studies, and proof-of-concept studies. Molecular imaging technologies promote the discovery and development of personalized medicine. Hong Zhang Mei Tian Carrio Ignasi Zhen Cheng Lie-Hang Shen David J. Yang

Molecular Imaging Of Integrin Alpha(V)Beta(6) Expression In Living Subjects

Molecular Imaging of Integrin Αvβ6 Expression in Living Subjects.

Molecular Imaging Probes for Integrin Α_vβ_3

Integrin Α6-Targeted Molecular Imaging of Central Nervous System Leukemia in Mice

Integrin Α6 Targeted Near Infrared Fluorescent Imaging and Photoacoustic Imaging of Hepatocellular Carcinoma in Mice

Integrin Α6-Targeted Positron Emission Tomography Imaging of Colorectal Cancer

Specific Detection Of Integrin Alpha(V)Beta(3) By Light-Up Bioprobe With Aggregation-Induced Emission Characteristics

First-in-human Pilot Study of an Integrin Α6-Targeted Radiotracer for SPECT Imaging of Breast Cancer

Integrin Alpha(V)Beta(6)-Targeted Spect Imaging for Pancreatic Cancer Detection

Interventional molecular imaging.

Development and Preclinical Evaluation of a Cyclic PET Tracer Targeting Integrin-Α6 on Colorectal Cancer Models

Advances on interventional molecular imaging

Radiolabeled Cyclic RGD Peptides As Radiotracers for Tumor Imaging.

Integrin Αvβ6–targeted SPECT Imaging for Pancreatic Cancer Detection

Molecular Imaging of Tumor Angiogenesis Using Rgd-Labeled Iron Oxide Nanoparticles

Tc-99m-Labeled Cystine Knot Peptide Targeting Integrin Alpha(V)Beta(6) For Tumor Spect Imaging

99Mtc-Hisodgr As a Potential SPECT Probe for Orthotopic Glioma Detection Via Targeting of Integrin Α5β1

99mTc-labeled cystine knot peptide targeting integrin αvβ6 for tumor SPECT imaging.

Molecular Image-Guided Theranostic and Personalized Medicine 2013

A Cystine Knot Peptide Targeting Integrin αvβ6 for Photoacoustic and Fluorescence Imaging of Tumors in Living Subjects

An Integrin Alpha 6-Targeted Radiotracer with Improved Receptor Binding Affinity and Tumor Uptake